Company Description
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.
It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors.
It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor.
The company has collaboration with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab.
I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Xi-Yong Fu |
Contact Details
Address: 2440 Research Boulevard, Suite 400 Rockville, Maryland 20850 United States | |
| Phone | 240 745 6330 |
| Website | i-mabbiopharma.com |
Stock Details
| Ticker Symbol | IMAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001778016 |
| CUSIP Number | 44975P103 |
| ISIN Number | US44975P1030 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Xi-Yong Fu M.B.A., Ph.D. | Chief Executive Officer and Director |
| Skelton Joseph | Chief Financial Officer |
| Tyler Ehler | Senior Director of Investor Relations |
| Dr. Phillip Dennis M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2025 | 6-K | Report of foreign issuer |
| Apr 3, 2025 | 6-K | Report of foreign issuer |
| Apr 3, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 21, 2025 | 6-K | Report of foreign issuer |
| Mar 7, 2025 | 6-K | Report of foreign issuer |
| Feb 27, 2025 | 6-K | Report of foreign issuer |
| Feb 5, 2025 | SCHEDULE 13D | Filing |
| Jan 29, 2025 | 6-K | Report of foreign issuer |
| Jan 13, 2025 | 6-K | Report of foreign issuer |
| Jan 8, 2025 | 6-K | Report of foreign issuer |